Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.

doi:10.1016/j.lungcan.2021.02.022

Article

Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2021

Volckmar Anna-Lena, Christopoulos Petros, Kirchner Martina, Allgäuer Michael, Neumann Olaf, Budczies Jan, Rempel Eugen, Horak Peter, Glade Julia, Goldschmid Hannah, Seker-Cin Huriye, Brandt Regine, Kriegsmann Mark, Leichsenring Jonas, Winter Hauke, Faehling Martin, Fischer Jürgen R, Heußel Claus Peter, Herth Felix, Brummer Tilman, Fröhling Stefan, Schirmacher Peter, Thomas Michael, Endris Volker, Penzel Roland, Kazdal Daniel, Bochtler Tilmann, Stenzinger Albrecht

Abstract excerpt

OBJECTIVES: Implementation of tyrosine kinase inhibitors (TKI) and other targeted therapies was a main advance in thoracic oncology with survival gains ranging from several months to years for non-small-cell lung cancer (NSCLC) patients. High-throughput comprehensive molecular profiling is of key importance to identify patients that can potentially benefit from these novel treatments. MATERIAL AND METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.

Abstract excerpt

Topics

Related research